… directed toward high conviction targets utilizing ProQR’s Axiomer technology INDIANAPOLIS; LEIDEN, Netherlands; and … announced in September 2021, applied ProQR’s proprietary Axiomer® RNA editing platform to target disorders of the …
… transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today reported its … at the RNA Editing Summit in Boston, highlighting its Axiomer technology platform and AX-0810, the Company’s … with meaningful changes in biomarkers in NHPs using Axiomer RNA Editing Oligonucleotides. At ASGCT, ProQR and …
… transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform today announced … will then be available for approximately 30 days. About Axiomer ™ ProQR is pioneering a next-generation RNA base editing technology called Axiomer ™ , which could potentially yield a new class of …
… Our leading intellectual property portfolio protects our Axiomer ® ADAR-mediated RNA editing platform technology and … patent protection related to its RNA editing platform, Axiomer ® , including more than 11 published patent families, … its IP estate around ADAR-mediated RNA editing. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today reported its … pleased with the continued progress in advancing our Axiomer ® RNA editing platform and believe we’re only at the … In November ProQR announced its IP estate surrounding its Axiomer ® RNA editing platform was further strengthened by: …
… the event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial … and mentored over 50 Ph.D. and M.S. degree students. About Axiomer ® ProQR is pioneering a next-generation RNA base editing technology called Axiomer ® , which could potentially yield a new class of …
… Announces Year End 2024 Operating and Financial Results Axiomer™ ADAR-mediated RNA editing pipeline advancing across … transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its …
… targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to … for cardiovascular diseases, and progress made across the Axiomer platform €89.4 million cash and cash equivalents as …
… transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the … perspective in guiding the Company in the translation of Axiomer, our leading RNA editing platform technology, to the …